从肾脏保护角度谈二肽基肽酶4抑制剂与钠-葡萄糖协同转运蛋白2抑制剂联合治疗2型糖尿病患者的潜在益处

Potential benefit of the combination therapy of dipeptidyl peptidase-4 inhibitor with sodium-glucose cotransporter-2 inhibitor in patients with type 2 diabetes mellitus： From the standpoint of renoprotection

二肽基肽酶4（DPP4）抑制剂与钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂均已被批准用于治疗2型糖尿病（T2DM）。研究显示，DPP-4抑制剂对肾脏组织结构受损具有潜在的改善作用，而SGLT-2抑制剂则可通过改善肾脏血流动力学而发挥肾脏保护作用。因此，DPP-4抑制剂与SGLT-2抑制剂联合治疗不仅可改善代谢控制水平，而且对于T2DM患者的肾脏结构和功能具有潜在的协同保护作用。这种联合治疗策略为改善T2DM患者综合管理水平提供了新的选择。

Both dipeptidyl peptidase-4 （ DPP-4 ） inhibitor and sodium-glucose cotransporter-2 （ SGLT-2 ） inhibitor have been approved for the treatment of type 2 diabetes mellitus（ T2DM）. In preclinical or clinical studies, DPP-4 inhibitor shows a potential beneficial effect on renal architecture damage, whereas SGLT-2 inhibitor has a role in renoprotection by improving renal hemodynamics. Therefore, the combination therapies with DPP-4 inhibitor and SGLT-2 inhibitor not only improve metabolic control, but also may have a synergistic or complementary effect in protecting renal structure and function in patients with T2DM. This combination therapy provides a novel option for raising the comprehensive management level in patients with T2DM.